|Bid||92.76 x 800|
|Ask||92.86 x 1000|
|Day's Range||91.27 - 93.59|
|52 Week Range||55.18 - 98.37|
|Beta (3Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||100.83|
Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality. BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.
IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of -4.35% and 6.03%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, Feb. 12, 2019 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today.
IRHYTHM TECH (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, Jan. 29, 2019 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today.
SAN FRANCISCO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC), a leading digital health company focused on the advancement of cardiac care, announced the publication of a new study in the January 2019 edition of Nature Medicine showing expert-level detection of cardiac arrhythmias using a new deep learning, or artificial intelligence, approach for electrocardiogram (ECG) analysis across a variety of diagnostic classes. The findings come from a collaboration with the Stanford Machine Learning Group that has resulted in the development of a cutting-edge deep learning model capable of arrhythmia detection at a level comparable to a panel of expert cardiologists for a total of 12 output classes.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
SAN FRANCISCO, Dec. 19, 2018 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of 2.27% and 7.61%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
If you’re interested in iRhythm Technologies Inc (NASDAQ:IRTC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
Three Motley Fool contributors offer second opinions on stocks that are attracting smart money.
Irhythm Technologies Inc (NASDAQ: IRTC ) dropped as much as 10.6 percent Wednesday after Apple Inc. (NASDAQ: AAPL ) announced FDA approval for an ECG scanner in its Watch Series 4. But as Street experts ...
IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of -21.43% and 9.10%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Thanks to a hefty amount of growth, high demand, fat margins and plenty of cash flow generation, both tech and healthcare stocks have surged since the end of the recession. Dubbed MedTech stocks, these firms feature plenty of innovative muscle. Which MedTech stocks have the goods to power your portfolio?